Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vonaprument - Annexon

Next Previous
Drug Profile

Vonaprument - Annexon

Alternative Names: Anti-C1q therapy - Annexon; ANX-007

Latest Information Update: 30 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Annexon
  • Class Antiglaucomas; Eye disorder therapies; Fab fragments; Monoclonal antibodies
  • Mechanism of Action Complement C1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Dry macular degeneration
  • No development reported Open-angle glaucoma

Most Recent Events

  • 24 Jul 2025 Annexon completes enrolment in the phase III ARCHER II trials in Dry macular degeneration (In the elderly, In adults) in USA (Intravitreous) (NCT06510816)
  • 12 May 2025 Annexon announces intention to submit regulatory application for Geographic atrophy secondary to age related macular degeneration in USA and Europe
  • 14 Nov 2024 Efficacy data from the phase II ARCHER trial in Dry macular degeneration released by Annexon Biosciences

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top